Key statistics dashboard for IGC Pharma, Inc. (IGC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage.
Stock Data
| Price | $0.27 |
| Market Cap | $27M |
| Enterprise Value | $28.0M |
| Beta | 0.31 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -3.30 |
| Price / Book | 4.45 |
| P/S | 24.24 |
| EV/EBITDA | -3.76 |
| EV/Sales | 24.91 |
| EV/FCF | -4.58 |
| P/FCF | -4.46 |
| Earnings Yield | -28.89% |
| FCF Yield | -22.41% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 21.91% |
| EBIT Margin | -688.60% |
| EBITDA Margin | -662.15% |
| Operating Margin | -986.82% |
| Net Margin | -702.14% |
| Return on Equity | -113.58% |
| Return on Assets | -83.03% |
| Return on Invested Capital | -153.62% |
| Return on Capital Employed | -176.44% |
Financial Health
| Current Ratio | 0.39 |
| Quick Ratio | 0.27 |
| Cash Ratio | 0.10 |
| Debt / Equity | 0.18 |
| Debt / Assets | 11.39% |
| Net Debt / EBITDA | -0.10 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | 0.06 |
| Cash per share | 0.00 |
| FCF per share | -0.06 |
| Tangible Book Value per share | 0.01 |
| Dividend per share | 0.00 |
Related companies: ANTX · BOLD · INTS · ITRM · NTRB · NXTC · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IGC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks